Compare Jumia Technologies AG - ADR (JMIA) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Nuwellis Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.24 (market cap $865.90M), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Jumia Technologies AG - ADR is far larger — about 393.6× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 1,695,227). Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Nuwellis Inc for 26 Days on average.
| JMIA | NUWE | |
|---|---|---|
Market Cap | $865.90M | $2.20M |
Volume | 1,695,227 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $146.65 |
52-Week Low | $5.69 | $0.68 |
Typical Hold Time | 28 Days | 26 Days |
Enterprise Value | $831.54M | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $6.315, down 6.31% today, amid a bearish technical signal. The company reported revenue of $188.93M in 2025 with a net loss of $61.55M, though losses are narrowing year-over-year. Analyst consensus is bullish with a $12.00 price target, and recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
The outlook hinges on JMIA achieving profitability targets, with upside potential from analyst targets but risks from persistent losses and high valuation multiples. Execution on cost control and African e-commerce growth are critical for stock performance, while cash flow volatility remains a concern.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
